Key Highlights

  • Third quarter net sales rose 3.1% to USD 2.063 billion, or 3.7% in constant currency.
  • Adjusted EPS of USD 1.90 beat the USD 1.88 estimate, while GAAP EPS fell 13.8% to USD 1.00.
  • Hips grew 6.0% and the technology and surgical group grew 11.9%, while Knees declined 3.1%.
  • Updated 2026 adjusted EPS guidance of USD 8.50 to USD 8.60 raises the low end from USD 8.47.

Zimmer Biomet (NYSE:ZBH) reported third quarter net sales of USD 2,062.9 million, up 3.1% from a year earlier and above the USD 2.04 billion estimate. Adjusted diluted EPS of USD 1.90 exceeded the USD 1.88 estimate and matched the prior-year figure. GAAP diluted EPS was USD 1.00, down 13.8%, on net Earnings of USD 191.6 million versus USD 230.9 million.

Franchise Mix and Geography

Growth varied sharply by product group. Hips sales rose 6.0% to USD 536.5 million, or 7.0% in constant currency. The S.E.T. group, which covers sports medicine, biologics, foot and ankle, upper extremities, trauma and related lines, grew 6.8% to USD 578.3 million. Technology and Data, Bone Cement and Surgical rose 11.9% to USD 180.6 million. Knees, the largest category at USD 767.5 million, declined 3.1%, with U.S. knee sales down 2.0% and international down 4.5%.

U.S. sales rose 3.6% to USD 1,205.6 million, and international sales rose 2.4% to USD 857.2 million, or 3.9% in constant currency. Chief executive Ivan Tornos said hips, S.E.T. and the technology group, together about two thirds of the business, grew at upper single digit or double-digit rates. For nine months, net sales were USD 6,326.6 million, up 5.7%, or 3.5% organically in constant currency.

Margins and Cash Flow

Adjusted gross Margin was 71.7%, compared with 72.6%, and adjusted Operating Margin narrowed to 25.1% from 26.5%. GAAP operating profit fell to USD 307.6 million from USD 351.3 million, a margin of 14.9% against 17.6%, partly because the year-earlier quarter included a USD 34.4 million benefit in Acquisition and integration items. Selling, general and administrative expense rose to USD 855.0 million from USD 811.4 million, while Research and Development eased to USD 105.9 million from USD 115.9 million.

Operating Cash Flow was USD 560.0 million and free cash flow was USD 372.4 million. Cash and equivalents stood at USD 399.9 million, down from USD 591.9 million at year end, and net Debt was USD 7,104.3 million compared with USD 6,927.2 million. Adjusted net earnings were USD 362.8 million.

Updated 2026 Guidance

Zimmer Biomet narrowed and lifted its outlook. Reported Revenue growth is now guided to 4.4% to 4.9%, up from 3.9% to 4.9%, and constant currency growth to 4.1% to 4.6%, up from 3.4% to 4.4%. Organic constant currency growth, which excludes about 110 basis points from the Paragon 28 acquisition, is guided to 3.0% to 3.5%, versus 2.25% to 3.25% before. Adjusted diluted EPS is guided to USD 8.50 to USD 8.60 from USD 8.47 to USD 8.59.

The company also extended a multi-year distribution and Supply agreement with THINK Surgical for robotics, opened an education Facility in Charlotte, North Carolina, and expanded its foot and ankle portfolio with two product launches.

Balance Sheet and Cash Markers

Quarterly free cash flow of USD 372.4 million compares with Operating Cash Flow of USD 560.0 million, while cash of USD 399.9 million sits against net debt of USD 7,104.3 million. Adjusted EPS of USD 1.90 compares with the full year guided range of USD 8.50 to USD 8.60, and the 71.7% adjusted gross margin compares with 72.6% a year earlier.